Ipratropiumbromide 40 Cyclocaps Teva

Ipratropium Bromide, the active ingredient in Ipratropiumbromide 40 Cyclocaps Teva, is an anticholinergic (muscarinic antagonist) presented as a 40 µg inhalation capsule (Cyclocaps) for inhalation use. It treats chronic obstructive pulmonary disease and asthma by relaxing airway smooth muscle and reducing mucus secretion.

GNH USA supplies Ipratropiumbromide 40 Cyclocaps Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide acts on the muscarinic receptors of the respiratory tract to improve airflow in obstructive airway diseases. - Chronic obstructive pulmonary disease (COPD): improves lung function and reduces exacerbations. - Asthma: provides adjunct bronchodilation for maintenance therapy. - Bronchospasm (e.g., exercise‑induced): offers short‑acting relief of airway narrowing.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Cough - Throat irritation - Headache - Dizziness - Altered taste perception

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Angioedema - Urinary retention - Increased intra‑ocular pressure - Cardiac arrhythmia

When prescribing Ipratropiumbromide 40 Cyclocaps, consider the following safety measures. - Assess respiratory status: evaluate baseline lung function before initiation. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or visual disturbances. - Use cautiously in narrow‑angle glaucoma: anticholinergic activity may worsen intra‑ocular pressure. - Avoid in patients with known hypersensitivity to ipratropium bromide or excipients. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Ipratropium bromide has a low systemic absorption profile, yet certain drug combinations require attention.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents (e.g., tiotropium) may increase anticholinergic burden. - Co‑administration with ophthalmic anticholinergics can exacerbate intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Combined therapy with β2‑agonists may produce additive bronchodilation; monitor for tachycardia. - Use with antihistamines possessing anticholinergic properties may enhance dry‑mouth effects. - Caution when given with drugs that affect cholinergic pathways, such as atropine.